86 related articles for article (PubMed ID: 10103145)
1. [Activation of the immune system in colorectal carcinoma and its assessment].
Jandík P; Melichar B; Mergancová J; Solichová D; Bures J; Voboril Z; Lukes J
Acta Medica (Hradec Kralove) Suppl; 1997; 40(2):81-2. PubMed ID: 10103145
[TBL] [Abstract][Full Text] [Related]
2. Urinary neopterin in patients with advanced colorectal carcinoma.
Melichar B; Solichová D; Melicharová K; Malírová E; Cermanová M; Zadák Z
Int J Biol Markers; 2006; 21(3):190-8. PubMed ID: 17013802
[TBL] [Abstract][Full Text] [Related]
3. Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer.
Zeimet AG; Reimer D; Schwentner L; Fuchs D; Wolf D; Fuith LC; Fiegl H; Doppler W; Concin N; Daxenbichler G; Marth C
Cancer Immunol Immunother; 2010 Dec; 59(12):1813-23. PubMed ID: 20717669
[TBL] [Abstract][Full Text] [Related]
4. Urinary neopterin concentrations during combination therapy with cetuximab in previously treated patients with metastatic colorectal carcinoma.
Melichar B; Kalábová H; Krčmová LK; Trivedi SV; Králíčková P; Malířová E; Pecka M; Študentová H; Zezulová M; Holečková P; Solichová D
In Vivo; 2014; 28(5):953-9. PubMed ID: 25189913
[TBL] [Abstract][Full Text] [Related]
5. Neopterin in renal cell carcinoma: inhalational administration of interleukin-2 is not accompanied by a rise of urinary neopterin.
Melichar B; Solichová D; Svobodová I; Melicharová K
Luminescence; 2005; 20(4-5):311-4. PubMed ID: 16134219
[TBL] [Abstract][Full Text] [Related]
6. Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO).
Volgger BM; Windbichler GH; Zeimet AG; Graf AH; Bogner G; Angleitner-Boubenizek L; Rohde M; Denison U; Sliutz G; Fuith LC; Fuchs D; Marth C
Ann Oncol; 2016 Sep; 27(9):1740-6. PubMed ID: 27358381
[TBL] [Abstract][Full Text] [Related]
7. Urinary neopterin in patients with liver tumors.
Melichar B; Solichová D; Svobodová I; Urbánek L; Veselý P; Melicharová K
Tumori; 2006; 92(4):318-22. PubMed ID: 17036523
[TBL] [Abstract][Full Text] [Related]
8. A New Diagnostic and Prognostic Marker in Endometrial Cancer: Neopterin.
Isci Bostanci E; Ugras Dikmen A; Girgin G; Gungor T; Baydar T; Nuri Danisman A
Int J Gynecol Cancer; 2017 May; 27(4):754-758. PubMed ID: 28383326
[TBL] [Abstract][Full Text] [Related]
9. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
[TBL] [Abstract][Full Text] [Related]
10. Different distribution of Dukes' stage between proximal and distal colorectal cancer.
Ikeda Y; Akagi K; Kinoshita J; Abe T; Miyazaki M; Mori M; Sugimachi K
Hepatogastroenterology; 2002; 49(48):1535-7. PubMed ID: 12397728
[TBL] [Abstract][Full Text] [Related]
11. Levels of soluble intercellular adhesion molecule-1 and total sialic acid in serum of patients with colorectal cancer.
Basoglu M; Yildirgan MI; Taysi S; Yilmaz I; Kiziltunc A; Balik AA; Celebi F; Atamanalp SS
J Surg Oncol; 2003 Jul; 83(3):180-4. PubMed ID: 12827689
[TBL] [Abstract][Full Text] [Related]
12. Urinary neopterin in malignant lymphoma.
Piccinini L; Zironi S; Federico M; Pini LA; Luppi G
Int J Biol Markers; 1991; 6(4):231-6. PubMed ID: 1795130
[TBL] [Abstract][Full Text] [Related]
13. Selection criteria for high risk and low risk groups of recurrence and metastasis in patients with primary colorectal cancer.
Mukai M; Sato S; Nishida T; Komatsu N; Shiba K; Nakasaki H; Makuuchi H
Oncol Rep; 2003; 10(6):1753-8. PubMed ID: 14534691
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
15. How many lymph nodes should be examined in Dukes' B colorectal cancer? Determination on the basis of cumulative survival rate.
Yoshimatsu K; Ishibashi K; Umehara A; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
Hepatogastroenterology; 2005; 52(66):1703-6. PubMed ID: 16334761
[TBL] [Abstract][Full Text] [Related]
16. Improvement of 10-year survival by Japanese radical lymph node dissection in patients with Dukes' B and C colorectal cancer: a 17-year retrospective study.
Mukai M; Ito I; Mukoyama S; Tajima T; Saito Y; Nakasaki H; Sato S; Makuuchi H
Oncol Rep; 2003; 10(4):927-34. PubMed ID: 12792747
[TBL] [Abstract][Full Text] [Related]
17. Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes' and AJCC stage in colorectal cancer.
Ramcharan SK; Lip GY; Stonelake PS; Blann AD
Eur J Clin Invest; 2013 Aug; 43(8):801-8. PubMed ID: 23683169
[TBL] [Abstract][Full Text] [Related]
18. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.
Mulder WM; Stern PL; Stukart MJ; de Windt E; Butzelaar RM; Meijer S; Adér HJ; Claessen AM; Vermorken JB; Meijer CJ; Wagstaff J; Scheper RJ; Bloemena E
Clin Cancer Res; 1997 Nov; 3(11):1923-30. PubMed ID: 9815581
[TBL] [Abstract][Full Text] [Related]
19. For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.
Caplin S; Cerottini JP; Bosman FT; Constanda MT; Givel JC
Cancer; 1998 Aug; 83(4):666-72. PubMed ID: 9708929
[TBL] [Abstract][Full Text] [Related]
20. Prognosis in Duke's B colorectal carcinoma: the Jass classification revisited.
De Quay N; Cerottini JP; Albe X; Saraga E; Givel JC; Caplin S
Eur J Surg; 1999 Jun; 165(6):588-92. PubMed ID: 10433145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
